May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Anti-Tumor Activity of Arginine Deiminase in Retinoblastoma
Author Affiliations & Notes
  • Y. S. Yu
    Ophthalmology/Coll of Med, Seoul National Univ Hosp, Seoul, Republic of Korea
  • J. Kim
    Ophthalmology/Coll of Med, Seoul National Univ Hosp, Seoul, Republic of Korea
  • S. Jeong
    Ophthalmology/Coll of Med, Seoul National Univ Hosp, Seoul, Republic of Korea
  • D. Kim
    Radiology, Chosun University Hospital, Kwangju, Republic of Korea
  • B. Min
    Department of Pharmacology College of Medicine, Korea University, Seoul, Republic of Korea
  • J. Kim
    Division of Pharmaceutical Bioscience, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
  • K.-W. Kim
    Division of Pharmaceutical Bioscience, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships Y.S. Yu, None; J. Kim, None; S. Jeong, None; D. Kim, None; B. Min, None; J. Kim, None; K. Kim, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5222. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. S. Yu, J. Kim, S. Jeong, D. Kim, B. Min, J. Kim, K.-W. Kim; Anti-Tumor Activity of Arginine Deiminase in Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5222.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To explore whether arginine deiminase (ADI), whose anti-tumor activity depends on argininosuccinate synthetase (ASS) activity, could be a potential anti-cancer agent of retinoblastoma

Methods:: In tumors of 20 retinoblastoma patients, argininosuccinate synthetase (ASS) expression was evaluated by immunohistochemistry. In retinoblastoma cell lines of Y79 and SNUOT-Rb1, ASS expression was checked by western blotting and RT-PCR. Anti-tumor activity of ADI was evaluated by cell count, LDH, and FACS. To evaluate ASS activity of these cell lines, anti-tumor activity of ADI in arginine+/citruline- condition was compared to that in arginine-/citruline+/ADI- condition.

Results:: In all retinoblastoma tumors and both retinoblastoma cell lines, ASS was highly detected. However, ADI significantly inhibited cell growth, induced cell death and apoptosis of both retinoblastoma cell lines. The anti-tumor activity of ADI in arginine+/citruline- condition was just same as that in arginine-/citruline+/ADI- condition.

Conclusions:: Our data suggests that ASS activity might be disturbed in some retinoblastoma and in these cases, ADI could be a potential anti-cancer agent of retinoblastoma. We are under the investigation for the mechanism of ASS activity loss in retinoblastoma.

Keywords: retinoblastoma • tumors • pathology: experimental 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×